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Asurvey ofa large series ofradiation- or chemically induced thymic lymphomas in (AKR XRF)FI, RF/J,
129/J, and C57BL/6Jmouse strains foractivated -as oncogenes showed that ofthe tumors containing trans-
formingactivity, in more than 75% ofthe cases this activity segregated with either K-ras or the N-ras gene.
H-ras activitiy was never detected. The genetic background ofthe host influenced susceptibility to tumor
induction and oncogene activation. TheK--as gene was preferentially activatedover theN-ras gene (approx-
imately 2:1) whether the inducing agent was radiation or the chemical N-nitrosomethylurea. The activat-
ingmutation forthe K-ras gene was consistently identified as a GGT to GAT transition in codon 12. In con-
trast, several different mutations of the N-ras gene were identified and localized to codons 12, 13, or 61.
Assessmentofthe allelic composition ofthe ias locus showsthatsomeproportion ofthetumors lostthenormal
ras allele.
Introduction
Induction ofgenetic alterations in DNA ofmammalsby
carcinogenic agents haslongbeen auseful model system
forunderstanding the events in cancer development. So-
matic mutations of specific cellular genes are known to
occur in human tumors and in a variety ofexperimental
animal tumors. Cellular genes belonging to the ras gene
family have been repeatedly identified in a significant
proportion of these human and animal tumors (1,2).
The ras gene family is comprised of three genes that
have homology in their DNA sequences. Two members
were identified in the oncogenic Harvey(H-ras) and Kir-
sten(K-ras) rat sarcomaviruses. The third member ofthe
family, N-ras, was isolated from a human neuroblastoma.
This family ofgenes encodes aprotein known as p21 due
to its mobility upon gel electrophoresis. It is highly con-
served in evolution and is normally expressed in mam-
mals in a tissue-specific manner (3,4).
The function of the p21 proteins is largely unknown.
However, the fact that they are so highly conserved in
evolution implies an important role in cell growth or
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differentiation orboth. The present evidence isforarole
in signal transduction (1). The ras proteins are located at
the inner surface ofthe cell membrane. Here they may
act as messengers to transmit signals receivedfrom out-
side the cell from hormones andgrowth factors to inside
the cell where the signal is translated as a message for
cell division.
The mechanism ofcarcinogen-induced oncogene activa-
tion is not understood. The genetic lesions that result in
activation ofthe ras cellulargene are single point muta-
tions. The presence ofthe mutation leads to a substitu-
tion ofamino acids that have been identified atpositions
12, 13, 61, or 117 of the p21 protein (1,5,6).
Experimental Animal Model of
Tumor Induction
In an attempt to understand some of the events in-
volved in carcinogen-induced tumors in man, we have
chosen to study tumorinduction in inbred strains ofmice.
Ionizing radiation, neutron radiation, and the DNA
alkylating agent N-nitrosomethylurea (NMU), all known
toproduce tumors in experimental animals, were chosen
for study. The inbred strains RF/J, C57BL/6, 129J,
BALB/c, and the F1 hybrid between AKR/J and RF/J
usedinthese studies eachprovide differentgeneticback-NEWCOMB ETAL.
grounds to determine the influence ofthe host on tumor
induction by the different agents.
Thymic lymphomas were induced in these strains of
mice with high frequency using well-defined treatment
protocols. Ionizinggammaradiation wasgiven according
to the Kaplan protocol of 4 weekly doses of 150 to 175
rads/dose beginning at 4 weeks of age (7). High LET
ionizing neutron radiation was used to treat 4-week-old
RF/J female mice once with 100 rads of 0.4 MeV neu-
trons. NMU treatment consisted of 5 weekly injections
IP (30 mg/kg) of4-week-old animals (8).
Several questions concerning tumor initiation and
progression can be addressed using animal model sys-
tems. Use ofgenetically identical mice ofdifferent strains
treated with the same carcinogenic agents will allow one
to determine whether the genetic background ofthe host
influences oncogene activation. A second question that is
of interest is whether treatment of the same strain of
mice with different carcinogenic agentsproduces activat-
ing mutations that are carcinogen specific. Last, since
cancer development is believed to be a multistage pro-
cess, we would like to determine at what stage oftumor
development ras genes are involved.
Methods for Detecting Transforming
DNA Sequences
The ability to detect transforming DNA sequences or
activated oncogenes is essential to the success ofstudy-
ingtheirrole(s) in tumor development. Thebiological ac-
tivity ofoncogenes is measured in assays where tumor-
derived DNA is introduced into mouse fibroblasts. The
presence of a transforming DNA sequence is scored by
achange inmorphology ofthemousefibroblastaftergene
transferbyfocusformationin5% calfserum. Underthese
conditions ofselection, transformed cells have agrowth
advantage over normal cells.
Another method that is able to detect transforming
genes that lack the ability to induce focus formation in
mouse fibroblasts is outlined in Figure 1. Tumor DNAis
cotransferred with a dominant selectable biochemical
marker. Cells that take up the foreign DNAwill survive
in the presence ofthe antibiotic G418 and form colonies.
After2weeks, the colonies are harvested forinoculation
into nude mice. Tumor formation is associated with the
presence oftransforming DNA sequences (9).
The transformation arisingin eitherthe focus assay or
the tumorigenicity assay are then subjected to molecu-
lar analysis to characterize theoncogene (ras ornon-ras)
and its activating mutation. Because the DNA gene
transfers were intraspecific, positive 3T3 transformants
were screenedby Southern blotanalysis forthepresence
of DNA rearrangements which occur when transfected
DNA sequences integrate into the NIH 3T3genome. The
ras genes are detected in high frequency in these 3T3
transformants as additional DNA bands over the en-
dogenous ras germline pattern. Amplification ofthe ac-
quired ras sequences is frequently observed in positive
transformants.
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FIGURE 1. Detection oftransforming activity in DNAs from carcinogen-
induced thymic lymphomas by the tumorigenicity assay.
Methods for Identifying Activating
ras Mutations
The genetic lesions that activate ras genes have been
identified as single point mutations in each of the ras
genes at similar sites. The codons 12, 13, or 61 are most
frequently involved in this family of oncogenes. Three
methods have been used in these studies to identify the
activating mutations in the K- and N-ras genes charac-
terized by Southern blot analysis. Two N-ras positive
transformants were cloned, and the ras DNAfragments
were sequenced to determine the activating mutations
(10). The presence of certain mutations is known to
change a restriction enzyme site, thus creating DNA
fragment polymorphisms that are easily detected in
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Southern blots. The most widely used method has been
oligonucleotide mismatch hybridization (11). Thismethod
isbased onthe difference inmeltingtemperature of a per-
fectly matched DNA-DNA hybrid relative to that of a
hybrid with a single base pair mismatch. Synthetic
oligonucleotides of 19 bases complementary to the nor-
mal 12th, 13th, or 61st codon ofthe N-ras gene and to the
normal 12th or 61st codon of the K-ras gene were pre-
pared. In addition, oligomers of 19 bases were prepared
for all possible mutations of these codons, each with a
base substitution at the middle position #10 of the
oligomer. Themutations werefirstidentified inthe NIH
3T3 transformants and then in the primary lymphoma
which served as the original source ofthe transforming
DNA.
Results
Tumor Induction and Detection of
Transforming Activity
The inbred strains RF/J, 129/J, C57BL/6J, and the F1
hybrids of(AKR/J x RF/J) mice were treated with the
Kaplan protocol offourfractionated doses ofgammaradi-
ation or with five NMU injections at weekly intervals.
Thymiclymphomas were inducedwithhighfrequency in
all groups ofmice by both carcinogenic treatments with
only one exception. 129/J mice were resistant to tumor
induction by gamma radiation but highly susceptible to
thymic lymphoma induction by NMU treatment.
Thymic lymphomas have also been induced in RF/J
mice by neutron irradiation. The frequency (65%) was
somewhat lower than that observedforradiation-induced
tumors (>90%). The latentperiod of6months, however,
was similar for both radiation-induced tumors in this
strain.
Tumor DNAs were screened for transforming activity
in NIH 3T3 cells using the calcium-phospate method of
DNA-mediated gene transfer(12). Eitherthefocus assay
or the nude mouse tumorigenicity assay ( Fig. 1) was
used. DNAs from carcinogen-induced thymiclymphomas
ofdifferent mouse strains varied in overall transforming
activity. Approximately 35% of the thymic lymphoma
DNAsfrom RF/Jand 129/Jmice were active in the focus-
forming assay (10). With the same assay, 60 to 80% of
carcinogen-induced tumors of (AKR times RF)F1 mice
produced 3T3 transformants (13). Tumors induced in
C57BL/6Jmice were analyzed inparallel inboth assays.
The nude mouse assay detected transforming activity in
80% of both groups of carcinogen-induced tumors,
whereas the focus assay was less sensitive. None ofthe
DNAs tested from radiation-induced thymic lymphomas
of C57BL/6J mice produced foci whereas 50% of the
DNAs from NMU-induced tumors were active (14).
Identification ofthe Carcinogen-Activated
Oncogene and Its Distribution
Initially the DNAs from the 3T3 transformants were
screened for ras sequences (H-, N-, and K-ras), as these
oncogenes are mostfrequently detected in this assay. A
total of58 tumors from all four strains ofmice produced
3T3 transformants. Ofthese, 78% had transforming ac-
tivity that segregated with eitherthe K-ras(28/58)orthe
N-ras (17/58)gene. Inno instance has H-ras activitybeen
detected in any carcinogen-induced thymic lymphomas.
The remaining22% (13/58) ofthe transformants did not
appeartobepositiveforany activated rasgeneby South-
ern blot analysis and p21 protein analysis. Preliminary
screening ofthese transformants with a panel ofknown
onocogene probes shows that they are negative formyb,
myc, neu, and raf.
The frequency distribution ofactivated ras oncogenes
in DNAs from NMU- or radiation-induced thymic lym-
phomas ofdifferent mouse strains is summarized in Ta-
ble 1. The K-ras gene waspreferentially activated, being
present in 50% of the DNAs from carcinogen-induced
tumors. Activation ofthe N-ras oncogene was observed
in29% ofthe tumor DNAs. The non-ras transforming ac-
tivitypresentinthelastgroup oftransformantsremains
to be identified.
The results of this survey would suggest that host
genes caninfluence thefrequency ofras gene activation
aswell as the type ofras gene, whichbecomes activated
as a result ofcarcinogen treatment. NMU treatment of
129/J or RF/J mice produced activation ofK- and N-ras
genes with similarfrequencies. In contrast, C57BL/6 or
(AKR x RF)Fi mice treated similarly with NMU show
preferential activation of K-ras or N-ras genes, respec-
tively. Likewise, radiation treatment of RF/J and
C57BL/6 mice produces tumors in which the K- and N-
rasgenes are activated inequalproportions. Onthe other
hand, the K-ras gene ispreferentially activated in (AKR
x RF)Fi mice following radiation treatment.
Table 1. Frequency distribution of ras oncogene activation in
carcinogen-induced thymic lymphomas in different mouse
strains.
Strain Treatment Characterization ofoncogenesa
of mouse of animal K-ras N-ras Non-rasb
(AKR x RF)F, y-rays ++++C _ -
N-methylnitrosourea - ++++ -
RF/J y-rays ++ + ++
N-methylnitrosourea + + + + + +
C57BL/6J y-rays + + + + +
N-methylnitrosourea ++++ - -
129/J y-rays NAd NA NA
N-methylnitorsourea + + + + + +
Number analyzed, 58 tumors 28 17 13
aNIH 3T3 transformants were obtained in the focus forming assay
or the nude mouse assay. DNAs from transformants were screened
for specific K- and N-ras sequences by Southern blot analysis and by
oligonucleotide mismatch hybridization.
bNIH 3T3 transformants negative for ras transforming sequences
were screened with a panel of known oncogene probes.
cFrequency distribution of ras and non-ras transforming se-
quences in NIH 3T3 transformants. Number oftransformants iden-
tified per total number ofpositive transformants analyzed: (+)
0-25%; (+ +) 26-50%; (+ ++) 51-75%; (+ + + +) 76-100%.
dNA, not applicable. 129/J mice are resistant to tumor induction.
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Analysis of Genetic Mutations in Activated
ras Oncogenes
The ras genepointmutations were identified by screen-
ing the DNA from the 3T3 transformants using the
oligonucleotide mismatch hybridization method. A total
of45 ras positive 3T3 transformants were analyzed and
point mutations were identified in30. Table2 summarizes
these results. Of28 K-raspositive3T3 transformants, 21
(75%) contained the G to A transition previously identi-
fied in codon 12 ofthe K-ras gene(15). Thismutation sub-
stitutes aspartate (GAT) forglycine (GGT). The remain-
ing 7 K-ras positive transformants contain a different
mutation(s) which has yet to be identified.
The mutations occurring in the N-ras gene, although
less frequently activated than the K-ras gene, were much
more heterogeneous in their nature. A total of 17 N-ras
positive transformants were analyzed. Mutations were
identified in 9 (53%) transformants, which affected all
three codons (12, 13, and 61).
Previously we have identified a CAA to AAA transver-
sion in the 61st codon ofthe N-ras gene that substitutes
glutamine for lysine (16). One-third ofthe N-ras positive
transformants contained this same mutation. An addi-
tional mutation was localized to codon 61 by cloning and
sequencing(10). This was aCAA to CTAmutation chang-
ing glutamine for leucine.
Approximately halfofthe mutations occurred as GGT
to GAT transitions in codon 12 (4 transformants) and in
codon 13(1 transformant). These mutations result in the
substitution of aspartate (GAT) for glycine (GGT).
Unknown genetic factors appear to influence which ras
gene becomes mutated, as well as the frequency with
which specific codons are mutated. NMU treatment of
C57BL/6 or (AKR x RF)F1 mice results in preferential
activation ofthe K-ras and N-ras genes respectively. As
shown in Table 2, the treatment ofRF/J strain mice with
two different agents, y radiation and the chemical NMU,
results in identical point mutations in the 12th codon of
the K-ras gene or the N-ras gene, arguing against car-
cinogen specific mutations in this mouse strain.
The K-ras gene is most frequently identified as the
transforming sequence in carcinogen-induced tumors of
all the strains of mice tested so far. The overwhelming
majority ofthe transformants contain the identical mu-
tation in codon 12, a GGT to GAT transition, irrespective
of the inducing agent used.
Somatic Loss ofNormal ras Allele in
Carcinogen-Induced Thymic Lymphomas
Homozygosity of abnormal genes is a frequently ob-
served phenomenon in several human malignancies
(17-19). We have reported loss ofthe normal N-ras allele
in one (AKR x RF)F1 NMU-induced thymic lymphoma
(20).
We therefore examined the allelic composition of some
ofthe DNAs from carcinogen-induced thymiclymphomas
that transferred activated K-ras genes. Using
oligonucleotide mismatch hybridization with oligomers
that recognize the normal and the mutated DNA se-
quences, primary tumors canbe screened for the dosage
ofthe allele variants. Four tumors analyzed to date show
homozygosity for the abnormal K-ras allele (10). Thus, it
appears that tumors with activated ras genes have a ten-
dency to lose the normal copy and/or increase the num-
ber ofcopies ofthe mutant allele (Fig. 2). This might be
one of the steps involved in tumor progression.
A workingmodel ofthe changes that may occur in vivo
in ras genes following carcinogen exposure is shown in
Figure 2. Initiation, the exposure to carcinogenic agents,
may result in mutation ofthe K- or N-ras genes directly
orindirectly throughthe action ofother genes. Mutations
that are relevantbiologically, i.e., confer agrowth advan-
tage to acell, are selected invivo. Duringtumor progres-
sion the mutated allele undergoes duplication. Subse-
quently, in some percentage of the tumors, the normal
ras allele is lost.
Conclusions and Perspectives
Inbred strains ofmice havebeentreatedwith different
carcinogenic agents, gamma or neutron radiation, and
N-nitrosomethylurea. These agents induce thymic lym-
phomas with highfrequency. Activation of oncogenes of
Table 2. Frequency distribution ofpoint mutations identified in activated ras oncogenes by mismatch hybridization.
Characterization ofmutation
Strain Treatment K-ras N-ras
of mouse of animal codon 12 Unknowna 12 13 61 Unknowna
(AKR x RF)F, y-rays +++b + - - - -
N-methylnitrosourea - - + - + +++
RF/J y-rays + + + + + - - -
N-methylnitrosourea + + + + + - + + +
C57BL/6J y-rays + ++ + +
N-methylnitrosourea +++++-
129/J y-rays NAC NA NA NA NA NA
N-methylnitrosourea +++ - ++ ++ - -
Number analyzed, 45 tumors 21 7 4 1 4 8
aUnknown mutation.
bFrequency distribution ofmas mutations in ras-positive NIH 3T3 transformants. Number of K- or N-ras mutations identified per total num-
ber of K- or N-ras positive transformants analyzed: (+) 0-25%; (++) 26-50%; (+ ++) 51-75% (+ + + +) 76-100%.
CNA, not applicable. 129/J mice are resistant to tumorinduction.
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FIGURE 2. A model of the role that ras genes may play at different
stages of carcinogen-induced disease.
the ras gene family have been systematically surveyed
inthese tumors. The main conclusions fromthese studies
are:
a)The genetic background ofthe hostmodifies the sus-
ceptibility ofa particular mouse strain to the action
ofa particular carcinogen (i.e., 129/J mice are resis-
tant to y irradiation).
b) The only ras oncogenes detected are K-ras and
N-ras.
c) Oncogene activation is not carcinogen specific (i.e.,
the same carcinogen activates different ras genes in
different mouse strains) but is modified by unknown
host genes.
d) Activation of the K-ras gene occurs predominantly
by a point mutation in codon 12 resulting in a GGT
to GAT transition.
e) Activation ofthe N-ras gene occurs by point muta-
tions in codons 12, 13, or 61.
f) Somatic loss of the normal N-ras or K-ras gene to-
gether with duplication ofthe mutated ras gene oc-
curs during tumor progression.
Our previous studies have used protocols requiring
multiple exposure ofthe animals to the carcinogen. More
recently, C57BL/6J, RF/J and 129/J mice were treated
with a single exposure to NMU (80 mg/kg). Similarly,
RF/J mice received a single exposure to neutron radia-
tion. Thymic lymphomas were induced in NMU-treated
C57BL/6J mice and neutron-irradiated RF/J mice. We
want to examine the frequency ofoncogene activation in
these tumors and identify the mutations. In addition, we
hope to be able to determine more precisely the timing
ofthe events outlined in Figure 2 that occur in high fre-
quency in ras genes in this model system of carcinogen-
induced murine thymic lymphoma.
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